198 related articles for article (PubMed ID: 19246334)
1. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Christogiannis LG; Bairaktari ET; Tselepis AD; Elisaf MS
J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):5-13. PubMed ID: 19246334
[TBL] [Abstract][Full Text] [Related]
2. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
[TBL] [Abstract][Full Text] [Related]
7. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
Milionis HJ; Rizos E; Kostapanos M; Filippatos TD; Gazi IF; Ganotakis ES; Goudevenos J; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2006 Jun; 22(6):1123-31. PubMed ID: 16846545
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
[TBL] [Abstract][Full Text] [Related]
9. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Ai M; Otokozawa S; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
Am J Cardiol; 2008 Feb; 101(3):315-8. PubMed ID: 18237592
[TBL] [Abstract][Full Text] [Related]
10. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
Ruisinger JF; Backes JM; Gibson CA; Moriarty PM
Am J Cardiol; 2009 Feb; 103(3):393-4. PubMed ID: 19166695
[TBL] [Abstract][Full Text] [Related]
11. Expanding options with a wider range of rosuvastatin doses.
Olsson AG
Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
[TBL] [Abstract][Full Text] [Related]
12. Review of efficacy of rosuvastatin 5 mg.
Teramoto T; Watkins C
Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
Gadarla M; Kearns AK; Thompson PD
Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
Underhill HR; Yuan C; Zhao XQ; Kraiss LW; Parker DL; Saam T; Chu B; Takaya N; Liu F; Polissar NL; Neradilek B; Raichlen JS; Cain VA; Waterton JC; Hamar W; Hatsukami TS
Am Heart J; 2008 Mar; 155(3):584.e1-8. PubMed ID: 18294500
[TBL] [Abstract][Full Text] [Related]
16. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
Hu M; Lee MH; Mak VW; Tomlinson B
Am J Cardiol; 2010 Dec; 106(11):1588-93. PubMed ID: 21094359
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
[TBL] [Abstract][Full Text] [Related]
19. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
[TBL] [Abstract][Full Text] [Related]
20. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
